The DOI matches its Crossref record; 349 of the 349 references it cites were found in a registry or an index.
Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer’s disease Neurons
Open accessAbstract
Amyloid-beta (Aβ) and hyperphosphorylated tau are hallmark lesions of Alzheimer’s disease (AD). However, the loss of synapses and dysfunctions of neurotransmission are more directly tied to disease severity. The role of these lesions in the pathoetiological progression of the disease remains contested. Biochemical, cellular, molecular, and pathological studies provided several lines of evidence and improved our understanding of how Aβ and hyperphosphorylated tau accumulation may directly harm synapses and alter neurotransmission. In vitro evidence suggests that Aβ and hyperphosphorylated tau have both direct and indirect cytotoxic effects that affect neurotransmission, axonal transport, signaling cascades, organelle function, and immune response in ways that lead to synaptic loss and dysfunctions in neurotransmitter release. Observations in preclinical models and autopsy studies support these findings, suggesting that while the pathoetiology of positive lesions remains elusive, their removal may reduce disease severity and progression. The purpose of this article is to highlight the need for further investigation of the role of tau in disease progression and its interactions with Aβ and neurotransmitters alike.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedJoshi, Y. B., Giannopoulos, P. F., Chu, J., Sperow, M., Kirby, L. G., Abood, M. E., & Praticò, D. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu412 · Cited by 42
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These findings led to the formulation of the “amyloid hypothesis” [95], which proposed that beta amyloid accumulation is responsible for AD-related pathology, including the initiation of neurofibrillary tangles (NFTs), and eventual neuronal death [96].”
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 2×
“In brief, A (cid:2) promotes glutamatergic excitotoxicity and disrupts glutamatergic synapses and plasticity providing an explanation for the cognitive deficits seen in AD [190].”
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Cited by
Free radicals and their impact on health and antioxidant defenses: a review
Chandimali, N., Bak, S. G., Park, E. H., Lim, H.-J., Won, Y.-S., Kim, E.-K., Park, S.-I., & Lee, S. J. (2025) · Cell Death Discovery · doi:10.1038/s41420-024-02278-8 · Cited by 669
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria
John, A., & Reddy, P. H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101208 · Cited by 359
“GABAAR agonists may protect neurons form the neurotoxicity of soluble Aβ by activating NMDARs during high frequency synaptic transmission (Rajmohan and Reddy, 2017).”
BackgroundSelf-citationRole of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Geraldo, L. H. M., Spohr, T. C. L. D. S., Amaral, R. F. D., Fonseca, A. C. C. D., Garcia, C., Mendes, F. D. A., Freitas, C., dosSantos, M. F., & Lima, F. R. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00367-5 · Cited by 313
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Astrocyte Senescence and Alzheimer’s Disease: A Review
Han, X., Zhang, T., Liu, H., Mi, Y., & Gou, X. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00148 · Cited by 177
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
Molecular Basis of Alzheimer’s Disease: Focus on Mitochondria
Oliver, D. M. A., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190048 · Cited by 120
Self-citationAlzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer’s disease patients
Domínguez-Álvaro, M., Montero-Crespo, M., Blazquez-Llorca, L., Insausti, R., DeFelipe, J., & Alonso-Nanclares, L. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0520-6 · Cited by 79
Sen, T., Saha, P., Jiang, T., & Sen, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916895117 · Cited by 68
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Metal Nanoparticles in Alzheimer’s Disease
Behera, A., Sa, N., Pradhan, S. P., Swain, S., & Sahu, P. K. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220112 · Cited by 50
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
Yin, X., Qiu, Y., Zhao, C., Zhou, Z., Bao, J., & Qian, W. (2021) · Medical Science Monitor · doi:10.12659/msm.933084 · Cited by 48
Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease
Kumar, S., Orlov, E., Gowda, P., Bose, C., Swerdlow, R. H., Lahiri, D. K., & Reddy, P. H. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00319-8 · Cited by 46
Self-citationGuo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
Mechanistic insights into the role of herpes simplex virus 1 in Alzheimer’s disease
Feng, S., Liu, Y., Zhou, Y., Shu, Z., Cheng, Z., Brenner, C., & Feng, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1245904 · Cited by 36
AZP2006, a new promising treatment for Alzheimer’s and related diseases
Callizot, N., Estrella, C., Burlet, S., Henriques, A., Brantis, C., Barrier, M., Campanari, M. L., & Verwaerde, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-94708-1 · Cited by 35
Ding, H., Reiss, A. B., Pinkhasov, A., & Kasselman, L. J. (2022) · Medicina · doi:10.3390/medicina58081025 · Cited by 32
TREM2 in neurodegeneration and diseases
Abdulkhaliq, A. A., Alasiri, G., Kim, B., Khan, J., Ajoolabady, A., Yousof, S. M., Ren, J., Tuomilehto, J., Borai, A., Alrfaei, B. M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03505-7 · Cited by 16
Rehman, H., Initiative, F. T. A. D. N., Ang, T. F. A., Tao, Q., Espenilla, A. L., Au, R., Farrer, L. A., Zhang, X., & Qiu, W. Q. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230837 · Cited by 7
Climacosa, F. M. M., Anlacan, V. M. M., Gordovez, F. J. A., Reyes, J. C. B., Tabios, I. K. B., Manalo, R. V. M., Cruz, J. M. C., Asis, J. L. B., Razal, R. B., Abaca, M. J. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078660 · Cited by 5
Metadata
- Authors
- Rajmohan, R., & Reddy, P. H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-08-26
- Volume
- 57
- Issue
- 4
- Pages
- 975-999
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2510053021
- Cited by
- 688
- References
- 349
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.